Cargando…

15-Epi-LXA(4) and MaR1 counter inflammation in stromal cells from patients with Achilles tendinopathy and rupture

Resolution of inflammation is poorly understood in Achilles tendon disorders. Herein, we investigated the bioactive lipid mediator profiles of tendon-derived stromal cells isolated from patients with Achilles tendinopathy (AT) or Achilles rupture (AR) under baseline and IL-1β–stimulated conditions....

Descripción completa

Detalles Bibliográficos
Autores principales: Dakin, Stephanie G., Colas, Romain A., Newton, Julia, Gwilym, Stephen, Jones, Natasha, Reid, Hamish A. B., Wood, Simon, Appleton, Louise, Wheway, Kim, Watkins, Bridget, Dalli, Jesmond, Carr, Andrew J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Federation of American Societies for Experimental Biology 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593888/
https://www.ncbi.nlm.nih.gov/pubmed/30916999
http://dx.doi.org/10.1096/fj.201900196R
_version_ 1783430144580386816
author Dakin, Stephanie G.
Colas, Romain A.
Newton, Julia
Gwilym, Stephen
Jones, Natasha
Reid, Hamish A. B.
Wood, Simon
Appleton, Louise
Wheway, Kim
Watkins, Bridget
Dalli, Jesmond
Carr, Andrew J.
author_facet Dakin, Stephanie G.
Colas, Romain A.
Newton, Julia
Gwilym, Stephen
Jones, Natasha
Reid, Hamish A. B.
Wood, Simon
Appleton, Louise
Wheway, Kim
Watkins, Bridget
Dalli, Jesmond
Carr, Andrew J.
author_sort Dakin, Stephanie G.
collection PubMed
description Resolution of inflammation is poorly understood in Achilles tendon disorders. Herein, we investigated the bioactive lipid mediator profiles of tendon-derived stromal cells isolated from patients with Achilles tendinopathy (AT) or Achilles rupture (AR) under baseline and IL-1β–stimulated conditions. We also determined whether incubating these cells with 2 of the mediators produced by tendon-derived stromal cells, 15-epi-Lipoxin A(4) (15-epi-LXA(4)) or maresin (MaR)-1, moderated their proinflammatory phenotype. Under baseline conditions, AT cells showed concurrent increased levels of proinflammatory eicosanoids and proresolving mediators compared with AR cells. IL-1β treatment induced profound prostaglandin E(2) release in AR compared with AT cells. Incubation of IL-1β treated AT and AR tendon-derived stromal cells in 15-epi-LXA(4) or MaR1 reduced proinflammatory eicosanoids and potentiated the release of proresolving mediators. These mediators also induced specialized proresolving mediator (SPM) biosynthetic enzymes arachidonate lipoxygenase (ALOX) 12 and ALOX15 and up-regulated the proresolving receptor ALX compared with vehicle-treated cells. Incubation in 15-epi-LXA(4) or MaR1 also moderated the proinflammatory phenotype of AT and AR cells, regulating podoplanin, CD90, signal transducer and activator of transcription (STAT)-1, IL-6, IFN regulatory factor (IRF) 5, and TLR4 and suppressed c-Jun N-terminal kinase 1/2/3, Lyn, STAT-3, and STAT-6 phosphokinase signaling. In summary, we identify proresolving mediators that are active in AT and AR and propose SPMs, including 15-epi-LXA(4) or MaR1, as a potential strategy to counterregulate inflammatory processes in these cells.—Dakin, S. G., Colas, R. A., Newton, J., Gwilym, S., Jones, N., Reid, H. A. B., Wood, S., Appleton, L., Wheway, K., Watkins, B., Dalli, J., Carr, A. J. 15-Epi-LXA(4) and MaR1 counter inflammation in stromal cells from patients with Achilles tendinopathy and rupture.
format Online
Article
Text
id pubmed-6593888
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Federation of American Societies for Experimental Biology
record_format MEDLINE/PubMed
spelling pubmed-65938882019-07-01 15-Epi-LXA(4) and MaR1 counter inflammation in stromal cells from patients with Achilles tendinopathy and rupture Dakin, Stephanie G. Colas, Romain A. Newton, Julia Gwilym, Stephen Jones, Natasha Reid, Hamish A. B. Wood, Simon Appleton, Louise Wheway, Kim Watkins, Bridget Dalli, Jesmond Carr, Andrew J. FASEB J Research Resolution of inflammation is poorly understood in Achilles tendon disorders. Herein, we investigated the bioactive lipid mediator profiles of tendon-derived stromal cells isolated from patients with Achilles tendinopathy (AT) or Achilles rupture (AR) under baseline and IL-1β–stimulated conditions. We also determined whether incubating these cells with 2 of the mediators produced by tendon-derived stromal cells, 15-epi-Lipoxin A(4) (15-epi-LXA(4)) or maresin (MaR)-1, moderated their proinflammatory phenotype. Under baseline conditions, AT cells showed concurrent increased levels of proinflammatory eicosanoids and proresolving mediators compared with AR cells. IL-1β treatment induced profound prostaglandin E(2) release in AR compared with AT cells. Incubation of IL-1β treated AT and AR tendon-derived stromal cells in 15-epi-LXA(4) or MaR1 reduced proinflammatory eicosanoids and potentiated the release of proresolving mediators. These mediators also induced specialized proresolving mediator (SPM) biosynthetic enzymes arachidonate lipoxygenase (ALOX) 12 and ALOX15 and up-regulated the proresolving receptor ALX compared with vehicle-treated cells. Incubation in 15-epi-LXA(4) or MaR1 also moderated the proinflammatory phenotype of AT and AR cells, regulating podoplanin, CD90, signal transducer and activator of transcription (STAT)-1, IL-6, IFN regulatory factor (IRF) 5, and TLR4 and suppressed c-Jun N-terminal kinase 1/2/3, Lyn, STAT-3, and STAT-6 phosphokinase signaling. In summary, we identify proresolving mediators that are active in AT and AR and propose SPMs, including 15-epi-LXA(4) or MaR1, as a potential strategy to counterregulate inflammatory processes in these cells.—Dakin, S. G., Colas, R. A., Newton, J., Gwilym, S., Jones, N., Reid, H. A. B., Wood, S., Appleton, L., Wheway, K., Watkins, B., Dalli, J., Carr, A. J. 15-Epi-LXA(4) and MaR1 counter inflammation in stromal cells from patients with Achilles tendinopathy and rupture. Federation of American Societies for Experimental Biology 2019-07 2019-03-27 /pmc/articles/PMC6593888/ /pubmed/30916999 http://dx.doi.org/10.1096/fj.201900196R Text en © The Author(s) http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International (CC BY 4.0) (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Dakin, Stephanie G.
Colas, Romain A.
Newton, Julia
Gwilym, Stephen
Jones, Natasha
Reid, Hamish A. B.
Wood, Simon
Appleton, Louise
Wheway, Kim
Watkins, Bridget
Dalli, Jesmond
Carr, Andrew J.
15-Epi-LXA(4) and MaR1 counter inflammation in stromal cells from patients with Achilles tendinopathy and rupture
title 15-Epi-LXA(4) and MaR1 counter inflammation in stromal cells from patients with Achilles tendinopathy and rupture
title_full 15-Epi-LXA(4) and MaR1 counter inflammation in stromal cells from patients with Achilles tendinopathy and rupture
title_fullStr 15-Epi-LXA(4) and MaR1 counter inflammation in stromal cells from patients with Achilles tendinopathy and rupture
title_full_unstemmed 15-Epi-LXA(4) and MaR1 counter inflammation in stromal cells from patients with Achilles tendinopathy and rupture
title_short 15-Epi-LXA(4) and MaR1 counter inflammation in stromal cells from patients with Achilles tendinopathy and rupture
title_sort 15-epi-lxa(4) and mar1 counter inflammation in stromal cells from patients with achilles tendinopathy and rupture
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593888/
https://www.ncbi.nlm.nih.gov/pubmed/30916999
http://dx.doi.org/10.1096/fj.201900196R
work_keys_str_mv AT dakinstephanieg 15epilxa4andmar1counterinflammationinstromalcellsfrompatientswithachillestendinopathyandrupture
AT colasromaina 15epilxa4andmar1counterinflammationinstromalcellsfrompatientswithachillestendinopathyandrupture
AT newtonjulia 15epilxa4andmar1counterinflammationinstromalcellsfrompatientswithachillestendinopathyandrupture
AT gwilymstephen 15epilxa4andmar1counterinflammationinstromalcellsfrompatientswithachillestendinopathyandrupture
AT jonesnatasha 15epilxa4andmar1counterinflammationinstromalcellsfrompatientswithachillestendinopathyandrupture
AT reidhamishab 15epilxa4andmar1counterinflammationinstromalcellsfrompatientswithachillestendinopathyandrupture
AT woodsimon 15epilxa4andmar1counterinflammationinstromalcellsfrompatientswithachillestendinopathyandrupture
AT appletonlouise 15epilxa4andmar1counterinflammationinstromalcellsfrompatientswithachillestendinopathyandrupture
AT whewaykim 15epilxa4andmar1counterinflammationinstromalcellsfrompatientswithachillestendinopathyandrupture
AT watkinsbridget 15epilxa4andmar1counterinflammationinstromalcellsfrompatientswithachillestendinopathyandrupture
AT dallijesmond 15epilxa4andmar1counterinflammationinstromalcellsfrompatientswithachillestendinopathyandrupture
AT carrandrewj 15epilxa4andmar1counterinflammationinstromalcellsfrompatientswithachillestendinopathyandrupture